AbbVie Inc.
$503.16B- Market cap
- $443.39B
- Debt
- +$65.00B
- Cash
- −$5.23B
Capital structure 87% equity / 13% debt · EV / Revenue 8.23x · EV proxy / EBITDA proxy 21.67x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $443.39B · View financials
Snapshot Sep 9, 2026, 4:00 PM ET
FY 2025 ·
Decision snapshot: ABBV stock price at premium vs A $250.91 current versus $74.75 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at A's multiple
Implied fair value · at ABBV's multiple
Snapshot Sep 9, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Multiple premium
Higher P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 87% equity / 13% debt · EV / Revenue 8.23x · EV proxy / EBITDA proxy 21.67x
Capital structure 92% equity / 8% debt · EV / Revenue 6.10x · EV proxy / EBITDA proxy 23.98x
ABBV carries the larger enterprise value at $503.16B against $42.37B; A trades on the lower EV / Revenue multiple (6.10x vs 8.23x); ABBV on the lower EV / EBITDA (21.67x vs 23.98x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AbbVie Inc. · implied price per share
Bear
$87.89
Base
$110.94
Bull
$142.98
AGILENT TECHNOLOGIES, INC. · implied price per share
Bear
$47.37
Base
$57.73
Bull
$71.70
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
ABBV vs PFE
Johnson & Johnson
ABBV vs JNJ
Merck & Co., Inc.
ABBV vs MRK
Eli Lilly and Company
ABBV vs LLY
Amgen Inc.
ABBV vs AMGN
Gilead Sciences, Inc.
ABBV vs GILD
THERMO FISHER SCIENTIFIC INC.
ABBV vs TMO
ILLUMINA, INC.
ABBV vs ILMN
BIO-TECHNE Corp
ABBV vs TECH
BRUKER CORP
ABBV vs BRKR
Azenta, Inc.
ABBV vs AZTA
WATERS CORP /DE/
ABBV vs WAT
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ABBV’s premium multiple is justified by sustained growth and superior capital efficiency, then hold or buy selectively; otherwise, reduce exposure because ABBV is priced far above both A-implied range and the DCF range despite only moderate quality signals and higher leverage.
ABBV trades at a large premium to A on both earnings and sales-based valuation, yet the implied P/E price is only $67.85 versus a current price of $255.65. The gap is driven by ABBV’s much higher P/E and EV-based multiples, while the current price remains near the upper end of its historical band.
Supporting Metrics